Status:
TERMINATED
Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients
Lead Sponsor:
AstraZeneca
Conditions:
Bipolar Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The primary purpose is to investigate whether the addition of sodium valproate will be superior to treatment with quetiapine (Seroquel) given as monotherapy for an additional 14 days in non-responding...
Eligibility Criteria
Inclusion
- Patients suffering from a manic or mixed episode.
Exclusion
- Patients who have not provided personal informed consent,
- Known intolerance, hypersensitivity or lack of antimanic response to sodium valproate or quetiapine fumarate,
- Involuntary admittance/detainment.
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00139074
Start Date
July 1 2005
End Date
June 1 2006
Last Update
January 28 2013
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Copenhagen, Denmark
2
Research Site
Esbjerg, Denmark
3
Research Site
Frederikssund, Denmark
4
Research Site
Haderslev, Denmark